Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.
about
Elucidating the immunological function of the Cryptococcus neoformans capsuleMonoclonal antibodies against peptidorhamnomannans of Scedosporium apiospermum enhance the pathogenicity of the fungusA histoplasma capsulatum-specific IgG1 isotype monoclonal antibody, H1C, to a 70-kilodalton cell surface protein is not protective in murine histoplasmosis.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2007-2008.Fungal vaccines and immunotherapeutics.High-throughput sequencing of human immunoglobulin variable regions with subtype identification.Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.B cells and antibodies in the defense against Mycobacterium tuberculosis infectionReleasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery.Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.Production and characterization of mouse monoclonal antibodies recognizing multiple subclasses of human IgG.Complementary MS methods assist conformational characterization of antibodies with altered S-S bonding networks.Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal diseaseContribution of murine IgG Fc regions to antibody binding to the capsule of Burkholderia pseudomallei.The capsule of the fungal pathogen Cryptococcus neoformans.A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.Carbohydrate vaccines: developing sweet solutions to sticky situations?Fc-receptors and immunity to malaria: from models to vaccines.Constant domains influence binding of mouse-human chimeric antibodies to the capsular polypeptide of Bacillus anthracis.Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.Cryptococcus antigens and immune responses: implications for a vaccine.Immunotherapy of Fungal Infections.An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.Plant production of anti-β-glucan antibodies for immunotherapy of fungal infections in humans.Structural and functional characterization of disulfide isoforms of the human IgG2 subclass.Host defense pathways against fungi: the basis for vaccines and immunotherapy.The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies.Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.Role of complement in protection against Cryptococcus gattii infection.The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding.Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis.Recent Advancements in Combinational Antifungal Therapy and Immunotherapy
P2860
Q26859234-F5B113E8-8963-491A-9A83-A23B59780DFFQ27306696-C1DF355C-3841-4124-A83E-1B662651CC27Q33962651-41BD0FF2-83AD-466B-B17E-EC6D3F251B10Q33995843-A6CA51EE-F662-43DA-BC95-7E3F99EE106CQ34400249-0FD278D0-7037-4782-BB00-DDADEB1C27B7Q34445962-3CA72EF1-FA7A-4D4A-A44B-11249720ABEDQ36192774-151F9AA8-7D51-44FD-9C9D-4598D64F4EAFQ36238031-A2BC4D12-D3C4-4511-8D92-1DC91CC2E1D4Q36331113-45FA3302-4647-4DAD-95B2-EF10A5DE43DEQ36513475-E24CC05E-CA6F-4536-A3C1-BC0562E6C2D7Q36571261-A6D8D7D3-D542-46C7-9D12-A4929609296DQ36836949-A9D1F86F-7B79-4032-9C7C-4C0954308A33Q37140093-F9A44D82-8C76-485F-8FC6-C8653BD46C2DQ37189868-76F39847-813B-4EAD-BF9C-2BE87ADA0F40Q37337879-17D4B950-1276-40FF-A023-A49A01351100Q37367575-5B653628-68FC-4F3B-90C8-3D615CE0D1FAQ37426039-8331BA51-8ABF-4BE8-9368-91557B34B8DFQ37582419-2410BD0F-F818-48B7-885E-5E52EBDE9316Q37713151-1B0BF095-FAC8-4CDA-BD56-9A863117D31AQ38011299-F4140D3C-3FA0-40F4-85F5-9A3D4E1EC125Q38155197-911209D1-47F5-43B8-AB7C-671A0154C49EQ38635409-A2F9AB64-9426-4755-A934-1B7C612A155FQ38880179-267A2550-75F0-477A-9067-36C8B1F30929Q39603076-CD724EF9-47FE-4FF4-86C0-C848CF1C44D7Q40446178-36532D1A-956E-4749-A9CD-77879250D102Q41901935-639C199D-82A9-4EF4-9B34-4C11B415F206Q42314996-15A1219C-AF4E-4CF3-B3AF-C88B70B62758Q43070206-DC8169FA-DD82-406F-8DF0-0AEFA482830DQ43179847-091C5115-242A-4797-8FCC-1335C619BD62Q47731094-49481809-BDB4-4DDA-9B4C-6EE0BF882C2DQ52719493-AC09F3B6-EBB2-4055-9E98-B63477CBC1B3Q55396489-DB86B381-BE82-4057-8F42-09CEE85808F4Q57705351-EF364994-8084-41AD-A6F2-0DB1C17DCA29
P2860
Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Human immunoglobulin G2 (IgG2) ...... tococcus neoformans infection.
@ast
Human immunoglobulin G2 (IgG2) ...... tococcus neoformans infection.
@en
type
label
Human immunoglobulin G2 (IgG2) ...... tococcus neoformans infection.
@ast
Human immunoglobulin G2 (IgG2) ...... tococcus neoformans infection.
@en
prefLabel
Human immunoglobulin G2 (IgG2) ...... tococcus neoformans infection.
@ast
Human immunoglobulin G2 (IgG2) ...... tococcus neoformans infection.
@en
P2093
P2860
P356
P1476
Human immunoglobulin G2 (IgG2) ...... ptococcus neoformans infection
@en
P2093
David O Beenhouwer
Esther M Yoo
Miguel A Rocha
Sherie L Morrison
P2860
P304
P356
10.1128/IAI.01161-06
P407
P50
P577
2007-01-12T00:00:00Z